CCC Co-Director Xinbin Chen
Oncology - Clinical Trials
Oncology - Clinical Trials
Thank you for allowing us the opportunity to play a part in your pet's health care. As a university teaching hospital, it is our goal to learn more about the debilitating cancers that our beloved pets experience. Through collaborations within and beyond UC Davis, we are conducting various cancer-related studies at the leading edge of cancer research. When your pet participates in one of our studies, you allow us the opportunity to increase our understanding of this debilitating disease that plagues loved ones, both humans and animals.
Canine patients with cancer
Canine patients with osteosarcoma
Canine patients with lymphoma
Feline patients with any type of cancer
Other studies
Cancer
Patient Disease
Canine patients that present to UCDAVIS with Soft Tissue Sarcoma, Transitional Cell Carcinoma of the bladder or Thyroid Cancer
Study Name
VEGFR Ultrasound Study
Purpose of the Study
The purpose of this study is to assess a novel ultrasound technique for its ability to approximate a tumors angiogenic potential. This technique involves the intravenous injection of a contrast agent that is targeted to a specific feature (vascular endothelial growth factor receptor or VEGFR density) of highly angiogenic blood vessels in the tumor. Our goal is to use this ultrasound technique to measure VEGFR density before therapy is instituted and compare this to special VEGFR stains of biopsied tumor tissue to ensure that the ultrasound technique truly approximates angiogenesis. This may allow us to prognosticate regarding future behavior of the tumor. In addition, we believe that this measure may act as a predictor of response to chemotherapy.
Eligibility Requirements
All dogs must be examined by a VMTH oncology or radiation oncology service veterinarian, and require the following baseline evaluations at the owners expense before a dog can be considered for enrollment in the trial:
- Confirmed cytologic diagnosis of transitional cell carcinoma, soft tissue sarcoma (including histiocytic sarcoma) or thyroid carcinoma
- No previous treatment is eligible for enrollment
- Dogs with a confirmed Tumor must be within 6 cm of the skin surface to be eligible
- Owners must opt for surgical resection and/or biopsy
- Physical examination with weight recorded
- CBC, Chemistry Panel and Urinalysis All within two weeks of enrollment (referring blood work is acceptable as long as it was ran at a commercial lab)
- Informed owner consent
Exclusion Criteria: Dogs will be excluded if they have evidence of cardiac disease or a history of anaphylactic reactions to vaccines, contrast agents or other medications. Dogs with any of the following characteristics are NOT eligible for enrollment:
- Creatinine > 3.0
- Bilirubin > 1.0
- ALT > 400 IU/L
- HCT < 25%
- Platelets < 50,000/µl
- Dogs with urethral stents
- Favorable performance status at the discretion of the treating clinician
Thoracic radiographs must be obtained to rule out evidence of severe cardiac disease.
Patient Disease
Canine patients with Bladder Cancer
Study Name
Quantitative Contrast Ultrasound Imaging of Canine Bladder Tumors
Purpose of the Study Bladder tumors are a relatively common type of cancer in dogs. They often are large enough or occur in a bad enough location that surgical removal is not possible. Thus, chemotherapy is the standard treatment with most dogs living for 6-12 months after diagnosis. Currently, there is no concensus regarding which chemotherapy results in the longest overall survival. Some dogs may have a better response to one type of chemotherapy while others respond better to a different type. The purpose of this study is to assess a novel ultrasound technique for its ability to predict whether a dog is responding to chemotherapy early in the course of treatment. This technique involves the intravenous injection of a contrast agent that allows for visualization of blood vessels in the tumor. Many chemotherapeutic agents will kill blood vessels as well as directly killing tumor cells as a way of 'starving' a tumor of oxygen and nutrients. We intend to use this ultrasound technique to measure blood vessels before chemotherapy and then at set intervals after the onset of chemotherapy in an attempt to determine if blood vessels in the tumor are dying. We anticipate that this will allow us to predict which dogs are responding to chemotherapy and ultimately to allow us to determine if a dog should continue with a particular chemotherapuetic or if they should be switched to another drug that might work better for that individual.
Eligibility Requirements
All dogs must be examined by a VMTH oncology or radiation oncology service veterinarian, and require the following baseline evaluations at the owners expense before a dog can be considered for enrollment in the trial:
- Confirmed diagnosis
- Physical examination with weight recorded
- CBC, Chemistry Panel and Urinalysis All within two weeks of enrollment (referring blood work is acceptable as long as it was ran at a commercial lab)
Baseline Evaluation for Eligibility
- Histologically or cytologically confirmed diagnosis of transitional cell carcinoma with no previous treatment
- Identifiable bladder mass
- No evidence of severe cardiac disease
- Informed owner consent
This study is partially funded; the cost of the ultrasounds is paid for. The owner is responsible for all other fees.
Patient Disease
Golden Retrievers with Cancer
Study Name
CCB02. The National Cancer Institute and UCDAVIS
Purpose of the Study
The National Cancer Institute is looking for Golden Retrievers with Mast Cell Tumors, and Hemangiosarcoma to participate in a clinical trial.
Eligibility Requirements
All dogs must be examined by a VMTH oncology, radiation oncology service or soft tissue surgery veterinarian at UCDavis, and require the following baseline evaluations at the owners expense before a dog can be considered for enrollment in the trial:
- Confirmed diagnosis
- Physical examination with weight recorded
Baseline Evaluation for Eligibility
- Histologically or cytologically confirmed disease
- Informed owner consent
- Surgery to be performed at UCDAVIS
Procedures:
If your Golden Retriever is eligible for any of the above mentioned cancer types, the study will pay for full-staging (CBC, Chemistry panel, Urine Analysis, Ultrasound, Radiographs) $800-$1000 of staging.
This is not a therapy, chemo or drug study. It is a tissue collection study to populate the tissue bank for future research. After your pets surgery you will be instructed to follow-up with an oncologist or your local veterinarian for follow-up care.
Please contact the Clinical Trials Coordinator at 530.752.0125 to find out if your pet is eligible.
Patient Disease
Canine patients with any cancers except lymphoma (must have measurable disease)
Study Name
Nanoparticle Taxol for the Treatment of Dogs with various tumor types
Purpose of the Study
Paclitaxel (Taxol) is a chemotherapy drug commonly used to treat a variety of human cancers including lung, breast, and prostate cancer. Many dogs are allergic to the carrier used in the human formulation to make the drug water-soluble. UC Davis Medical has developed a nanoparticle formulation of Taxol that allows safe administration of the drug to dogs and we have determined the dose appropriate for regular administration. Early data suggests that Taxol may be useful against a variety of canine cancers including osteosarcoma, mast cell tumor, mammary tumor, and histiocytic sarcoma.
Eligibility Requirements
All dogs must be examined by a VMTH oncology or radiation oncology service veterinarian, and require the following baseline evaluations at the owners expense before a dog can be considered for enrollment in the trial:
- Confirmed diagnosis
- hysical examination with weight recorded
- CBC, Chemistry Panel and Urinalysis All within two weeks of enrollment (referring blood work is acceptable as long as it was ran at a commercial lab)
Baseline Evaluation for Eligibility
- Histologically or cytologically confirmed disease
- At least one measurable affected organ
- Informed owner consent
This study is partially funded; the cost of the drug is paid for. The owner is responsible for all other fees (approximately $200-300 a visit)
Patient Disease
Dogs with Soft Tissue Sarcoma
Study Name
Assessment of Potential Tumor Tissue Effects Induced by a Single Intravenous Dose of TH-302 in Tumor Bearing Dogs
Purpose of the Study
To determine the degrees of chronic hypoxia in tumor tissue, and subsequently, the effects of TH-302, if any, on tumor tissue when administered as a one time intravenous bolus to canine patients with spontaneous soft tissue sarcoma 24 hors before their surgical resections.
Patient Entry Criteria
Dogs with Soft Tissue Sarcoma (STS) with measurable disease that is accessible from the outside, a strong surgical candidate.
Owner Responsibilities
As the owner you will be responsible for travel to UC Davis Veterinarian Teaching Hospital for treatment and follow-up care.
Financial Incentives
The study will pay for the pre-surgical biopsy, study drug, up to $2000 toward surgical excision, the follow-up bloodwork and exams. Additionally, should a side effect occur resulting from the procedure, the study will pay for $5000 (per event). All tests and treatments must be performed at the UC Davis VMTH.
Enrollment Status
Pending For questions regarding this clinical trial or any others listed, please call the clinical trials coordinator at: 530.752.0125
Osteosarcoma
Patient Disease
Canine Patients with Osteosarcoma
Study Name
Pathologic fracture risk of tumor-bearing canine antebrachii
Purpose of the Study
The objective of this study is to measure the reduction in bone strength due to the presence of osteosarcoma in the radius/ulna of the dog by measuring the force at which these bones break in a mechanical testing device. These measurements obtained by testing tumor-bearing bones from clinical patients will be compared to measurements performed in normal bones. Tumor–bearing bones will be obtained from clinical canine patients that are undergoing amputation of the affected limb as standard of care treatment for their bone tumor, and testing of these limbs will not affect care received by these patients. Computed tomography (CT) images of these bones will also be obtained, and this study will seek to correlate calculated CT indices of bone strength with the biomechanically measured bone strength. It is hoped that correlations found will allow prediction of patients at most risk for pathologic fracture, improve patient selection for current treatment options such as palliative radiation therapy, and aid in the development of new minimally invasive limb-salvage procedures.
Eligibility Requirements
All dogs must be examined by a VMTH oncology, radiation oncology service or soft tissue surgery veterinarian, and require the following baseline evaluations at the owners expense before a dog can be considered for enrollment in the trial:
- Confirmed diagnosis
- Physical examination with weight recorded
- CBC, Chemistry Panel and Urinalysis All within two weeks of enrollment (referring blood work is acceptable as long as it was ran at a commercial lab)
Baseline Evaluation for Eligibility
- Histologically or cytologically confirmed disease
- Disease in the radius/ulna
- Surgery performed by UCDAVIS Soft Tissue Surgery Department
- Informed owner consent
Procedures
1) CT of your dog’s forelimbs under general anesthesia BEFORE surgical removal
2) Biomechanical testing of your dog’s amputated limb AFTER surgical removal
Your dog is presenting to the UC Davis VMTH for treatment of a primary bone tumor of the distal radius (end of the front leg) by forelimb amputation. Amputation is currently the standard of care treatment to remove the tumor with wide margins with the fewest potential complications. If you agree to allow your animal to participate, he/she will be treated as usual in terms of his/her clinical workup and staging. At the time your dog is anesthetized for his/her amputation procedure, you agree to allow us to perform a computed tomography (CT) scan with and without intravenous contrast of your dog’s front legs (both legs will be done in the same scan) to image the tumor. While CT imaging is commonly performed as part of surgical planning for other diseases, this is unlikely to specifically benefit your dog as amputation is designed to remove the tumor with wide margins and CT results are not likely to alter the surgical plan. CT imaging is anticipated to require 30 minutes of anesthesia additional to that required for normal clinical management for the surgical procedure. Amputation of the limb will be performed as usual, and there will be no further deviations in the clinical care of your dog as recommended by the Surgery Service. After the limb with the tumor is removed, it will be taken for biomechanical testing. Once biomechanical testing is completed, the tumor or a portion of it will be submitted for histopathologic analysis as per standard of care.
Benefits
CT of Forelimbs and $325 applied toward total cost of your dog’s anesthesia, which covers the first two hours of anesthesia. This will cover the anticipated time needed to perform the CT imaging (30 minutes) as well as provide a financial benefit to allowing your pet to participate in this study as the remainder of this time will be applied toward your dog’s surgical procedure. You will be financially responsible for the charges associated with the clinical care of your dog beyond the stipend provided.
Patient Disease
Canine Patients with Osteosarcoma, Lymphoma, or Oral Malignant Melanoma, Mast Cell Tumors, Soft Tissue Sarcomas/ Histiocytic Sarcoma/Malignant Histocytosis, Primary Pulmonary Cancer, Hemangiosarcomas Study Name: Canine Comparative Oncology and Genomics Consortium (CCOGC) A Tissue Procurement Program
Purpose of the Study
UC Davis in collaboration with Pfizer-CCOGC Biospecimen Repository is collecting samples to populate a tissue bank for future research studies. The goal of the CCOGC and UC Davis will be to populate the Pfizer-CCOGC Biospecimen Repository with diseased tissues and specific normal tissues from dogs with cancer over the next three years. The study is guided by the National Cancer Institute (NCI). After receiving consent from owners, a sample of the tumor is banked following the CCOGC criteria and will be stored for future use of investigators with the ultimate goal of developing a treatment and prevention for the variety of cancers.
Patient Entry Criteria
Canine Lymphoma
- Owner consent to allow collection of the clinical specimens and to comply with follow-up and treatment requirements
- General clinical evaluation: Medical history, physical exam, complete blood count, biochemical profile, and urinalysis
- No prior chemotherapy
- No steroid therapy within two weeks of sampling.
Optional
- Histological diagnosis
- Complete staging evaluation Thoracic and abdominal radiographs (or ultrasound), BM aspiration cytology (all sites and stages acceptable)
- Histology of primary site
Canine Osteosarcoma
- Owner consent to allow collection of the clinical specimens and to comply with follow-up and treatment requirements
- General clinical evaluation: Medical history, physical exam, complete blood count, biochemical profile, and urinalysis
- Histological diagnosis
- Complete staging evaluation, including thoracic radiographs
- Appendicular or axial but tumor must be excised to allow for tissue collection
- Histology of primary site
Canine Oral Malignant Melanoma
- Owner consent to allow collection of the clinical specimens and to comply with follow-up and treatment requirements
- General clinical evaluation: Medical history, physical exam, complete blood count, biochemical profile, and urinalysis
- Histological diagnosis
- Complete staging evaluation, to include cytology or histology of submandibular lymph nodes, thoracic radiographs
- Histology of primary site
Canine Soft Tissue Sarcoma/Histiocytic Sarcoma/ Malignant Histiocytosis
- Owner consent to allow collection of the clinical specimens and to comply with follow-up and treatment requirements
- General clinical evaluation: Medical history, physical exam, complete blood count, biochemical profile, and urinalysis
- Clinical presentation consistent with STS/HS/MH (Histiological diagnosis confirmed post collection).
- Complete staging evaluation, including thoracic radiographs
- Tumors in any location (Viscera, lung) are eligible
Canine Primary Pulmonary Tumors
- Owner consent to allow collection of the clinical specimens and to comply with follow-up and treatment requirements
- General clinical evaluation: Medical history, physical exam, complete blood count, biochemical profile, and urinalysis
- Clinical presentation consistent with Pulmonary Tumor (Histological diagnosis confirmed post collection).
- Surgical excisionor collection immediately following euthanasia.
Canine Mast Cell Tumor
- Owner consent to allow collection of the clinical specimens and to comply with follow-up and treatment requirements
- General clinical evaluation: Medical history, physical exam, complete blood count, biochemical profile, and urinalysis
- Cytological staging evaluation
- Histology of primary site
- Tumor should be greater than 2cm
Please talk to your oncologist at the time of your visit to find out how your dog can contribute to future research studies by submitting a small sample of your dogs cancer.
Patient Disease
Canine patients with Osteosarcoma that elect not to receive standard IV chemotherapy
Study Name
Naïve Osteosarcoma/Amputated
Purpose of the Study
The goal of this study is to evaluate how well low doses of Gemcitabine control the micro-metastatic disease in the lungs when given as an inhalant.
Eligibility Requirements
Any prospective patient must be examined by the VMTH Oncology or Radiation Oncology service veterinarian, and require the following baseline evaluations at the owners expense before a dog can be considered for enrollment in the trial:
- Confirmed diagnosis
- Physical examination with weight recorded
- CBC, Chemistry Panel and Urinalysis All within two weeks of enrollment (referring blood work is acceptable as long as it was run at a commercial lab)
Baseline Evaluation for Eligibility
- Histologically or cytologically confirmed disease
- Amputation
- No visible Metastasis in the Lungs as noted by a radiologist
- Informed owner consent
- Owner must be able to perform treatments at home
- Return once a month for routine bloodwork and Radiographs
Financial Incentive
This study is Fully Funded through donations and grants. Once enrolled, the study will pay for office exam, routine bloodwork, and radiographs (while on study). Please note, participation from owner is necessary. Owner is responsible for performing the aerosol treatments at home.
Patient Disease
Canine patients with Osteosarcoma with confirmed Metastasis to the lungs
Study Name
Relapsed Osteosarcoma/Amputated with metastasis to the lungs
Purpose of the Study
The goal of this study is to evaluate the efficacy of Ifosfamide IV in addition to aerosolized Gemcitabine in dogs with relapsed gross metastatic disease.
Eligibility Requirements Any prospective patient must be examined by the VMTH Oncology or Radiation Oncology service veterinarian, and require the following baseline evaluations at the owners expense before a dog can be considered for enrollment in the trial:
Confirmed diagnosis
- Physical examination with weight recorded
- CBC, Chemistry Panel and Urinalysis All within two weeks of enrollment (referring blood work is acceptable as long as it was run at a commercial lab)
Baseline Evaluation for Eligibility
- Histologically or cytologically confirmed disease
- Amputation
- Visible Metastasis in the Lungs as noted by a radiologist
- Informed owner consent
- Owner must be able to perform treatments at home.
- Return every three weeks for IV treatment of Ifosfamide and bloodwork.
Financial Incentive
This study is partially funded. The owner will be responsible for the cost of the Ifosfamide treatment every 3 weeks. The study will pay for every other radiographic evaluation taken while on study. In addition, the cost of the aerosol Gemcitabine is covered under the study. Owner is responsible for performing the aerosol treatments at home.
Lymphoma
Patient Disease
Dogs with Lymphoma/SH-7139
Study Name
Preclinical evaluation of a novel synthetic antibody for treatment of spontaneously occurring B-cell lymphoma in dogs.
Purpose of the Study
It is possible that treatment with SH 7139 will be an effective therapy for your dog’s lymphoma, and may result in remission. It is hoped that with the information obtained from this trial, SH 7139 can proceed to clinical trials in people with non-Hodgkin’s lymphoma.
Eligibility Requirements/Patient Entry Criteria:
The study will enroll adult dogs of any breed with peripheral lymphadenopathy, with confirmed B-cell lymphoma, with a life expectancy of at least 6 weeks. This study intends to recruit both newly diagnosed cases without previous treatment, and relapsed patients that may have failed other treatment options.
All dogs must be examined by a VMTH oncology or radiation oncology service veterinarian, and require the following baseline evaluations at the owners expense before a dog can be considered for enrollment in the trial:
- Confirmed diagnosis
- Physical examination with weight recorded
- CBC, Chemistry Panel and Urinalysis All within two weeks of enrollment (referring blood work is acceptable as long as it was ran at a commercial lab)
Baseline Evaluation for Eligibility
- Histologically or cytologically confirmed disease
- At least one measurable affected organ
- Informed owner consent
Financial Incentives
Dog owners participating in this study will be given special financial considerations. This is a fully funded trial, once the patient is determined eligible by the oncologist. The study will pay for the cost of the weekly exam fees, bloodwork, anti-body drug.
Owner’s Responsibilities
The owner will be responsible for scheduling appointments with the study coordinator and keeping those appointments as required by protocol. Owners also have the responsibility to cover the cost of the initial examination and blood work and any additional medications prescribed.
Patient Disease
Dogs with Lymphoma
Study Name
Novel Product Targeting Canine B-Cell and T-Cell Lymphoma
Purpose of the Study
Lymphoma is one of the most common blood cancers affecting dogs of different type of breeds and ages. Lymphoma is a devastating disease that, when left untreated, will lead to death in weeks. There is no cure known to this disease. Current treatments involve the use of extensive chemotherapy and / or radiotherapy, resulting generally in an initial response followed by relapse, and eventually resistance. Further, these treatments may be associated with severe side effects affecting patient’s quality of life. Therefore, a more effective and safe treatment for canine lymphoma is urgently needed.
New treatments based on the use of tumor targeting Product (non-chemotherapeutic agents) have been developed and used for the treatment of lymphoma in humans achieving an improved treatment efficacy with survival extension and an improved quality of life while significantly reducing toxicity. These treatments have proven to be groundbreaking for humans.
This Product is designed specifically for dogs. This Product was shown to be safe in normal dogs and effective at depleting lymphoma cells in laboratory studies.
This study proposes the use of this Product to obtain additional data about its safety and its Pharmacokinetic and Pharmacodynamic properties in dogs with lymphoma.
Patient Entry Criteria
The study will enroll adult dogs of any breed with peripheral lymphadenopathy, with confirmed B-cell lymphoma or T-Cell lymphoma, with a life expectancy of at least 6 weeks. This study intends to recruit both newly diagnosed cases without previous treatment, and first relapsed.
Financial Incentives
Dog owners participating in this study will be given special financial considerations. The study will pay for the cost of the Product, which is not available anywhere outside the study, and will also cover for the cost of examination and blood work required by the study protocol after enrollment.
Owner’s Responsibilities
The owner will be responsible for scheduling appointments with the study coordinator and keeping those appointments as required by protocol. Owners also have the responsibility to cover the cost of the initial examination and blood work and any additional medications prescribed.
Patient Disease
Canine Patients with Osteosarcoma, Lymphoma, or Oral Malignant Melanoma, Mast Cell Tumors, Soft Tissue Sarcomas/ Histiocytic Sarcoma/Malignant Histocytosis, Primary Pulmonary Cancer, Hemangiosarcomas Study Name: Canine Comparative Oncology and Genomics Consortium (CCOGC) A Tissue Procurement Program
Purpose of the Study
UC Davis in collaboration with Pfizer-CCOGC Biospecimen Repository is collecting samples to populate a tissue bank for future research studies. The goal of the CCOGC and UC Davis will be to populate the Pfizer-CCOGC Biospecimen Repository with diseased tissues and specific normal tissues from dogs with cancer over the next three years. The study is guided by the National Cancer Institute (NCI). After receiving consent from owners, a sample of the tumor is banked following the CCOGC criteria and will be stored for future use of investigators with the ultimate goal of developing a treatment and prevention for the variety of cancers.
Patient Entry Criteria
Canine Lymphoma
- Owner consent to allow collection of the clinical specimens and to comply with follow-up and treatment requirements
- General clinical evaluation: Medical history, physical exam, complete blood count, biochemical profile, and urinalysis
- No prior chemotherapy
- No steroid therapy within two weeks of sampling.
Optional
- Histological diagnosis
- Complete staging evaluation Thoracic and abdominal radiographs (or ultrasound), BM aspiration cytology (all sites and stages acceptable)
- Histology of primary site
Canine Osteosarcoma
- Owner consent to allow collection of the clinical specimens and to comply with follow-up and treatment requirements
- General clinical evaluation: Medical history, physical exam, complete blood count, biochemical profile, and urinalysis
- Histological diagnosis
- Complete staging evaluation, including thoracic radiographs
- Appendicular or axial but tumor must be excised to allow for tissue collection
- Histology of primary site
Canine Oral Malignant Melanoma
- Owner consent to allow collection of the clinical specimens and to comply with follow-up and treatment requirements
- General clinical evaluation: Medical history, physical exam, complete blood count, biochemical profile, and urinalysis
- Histological diagnosis
- Complete staging evaluation, to include cytology or histology of submandibular lymph nodes, thoracic radiographs
- Histology of primary site
Canine Soft Tissue Sarcoma/Histiocytic Sarcoma/ Malignant Histiocytosis
- Owner consent to allow collection of the clinical specimens and to comply with follow-up and treatment requirements
- General clinical evaluation: Medical history, physical exam, complete blood count, biochemical profile, and urinalysis
- Clinical presentation consistent with STS/HS/MH (Histiological diagnosis confirmed post collection).
- Complete staging evaluation, including thoracic radiographs
- Tumors in any location (Viscera, lung) are eligible
Canine Primary Pulmonary Tumors
- Owner consent to allow collection of the clinical specimens and to comply with follow-up and treatment requirements
- General clinical evaluation: Medical history, physical exam, complete blood count, biochemical profile, and urinalysis
- Clinical presentation consistent with Pulmonary Tumor (Histological diagnosis confirmed post collection).
- Surgical excisionor collection immediately following euthanasia.
Canine Mast Cell Tumor
- Owner consent to allow collection of the clinical specimens and to comply with follow-up and treatment requirements
- General clinical evaluation: Medical history, physical exam, complete blood count, biochemical profile, and urinalysis
- Cytological staging evaluation
- Histology of primary site
- Tumor should be greater than 2cm
Please talk to your oncologist at the time of your visit to find out how your dog can contribute to future research studies by submitting a small sample of your dogs cancer.
Patient Disease
Canine patients with Lymphoma or Oral Malignant Melanoma
Study Name
P.A.G.
Purpose of the Study
The goal of this study is to evaluate the efficacy of using the enzyme Pegylated Arginine Deiminase (non-chemotherapy drug) as a subcutaneous injection.
Eligibility Requirements
Any prospective patient must be examined by the VMTH Oncology or Radiation Oncology service veterinarian, and require the following baseline evaluations at the owners expense before a dog can be considered for enrollment in the trial:
- Confirmed diagnosis
- Physical examination with weight recorded
- CBC, Chemistry Panel and Urinalysis All within two weeks of enrollment (referring blood work is acceptable as long as it was run at a commercial lab)
Baseline Evaluation for Eligibility
- Histologically or cytologically confirmed disease
- Measurable and biopsiable tumor
- Ability to stay overnight
- Dog has to be greater than 10kg
- Informed owner consent
Financial Incentive
This study is fully funded. Please contact the Oncology department for more information.
This is a Phase I study.
Feline
Patient Disease
Feline Patients with Any Tumor Type
Study Name
Gemzar (Gemcitabine) for Cats
Purpose of the Study
The purpose of the study is to determine the dose of Gemcitabine that optimizes tumor control in cats with any type of tumor.
Eligibility Requirements
Any prospective patient must be examined by the VMTH Oncology or Radiation Oncology service veterinarian, and require the following baseline evaluations at the owners expense before a cat can be considered for enrollment in the trial:
- Confirmed diagnosis
- Physical examination with weight recorded
- CBC, Chemistry Panel and Urinalysis All within one weeks of enrollment (referring blood work is acceptable as long as it was run at a commercial lab)
Baseline Evaluation for Eligibility
- Histologically or cytologically confirmed disease
- Any cat with any tumor type, must be in stable condition
- Normal bloodwork within one week
- Informed owner consent
Financial Incentive
This study is Fully Funded. Once enrolled, the study will pay for the office exam, routine bloodwork, administration of the drug and drug. The patient will be required to stay at least part of the day.
Other Studies
Patient Disease
Canine patients with any tumor type scheduled for surgery at UCDAVIS
Study Name
Intratumoral concentrations of enrofloxacin and its metabolite ciprofloxacin in spontaneously arising canine tumors
Purpose of the Study
Preliminary data in our laboratory and others indicates that the fluoroquinolone class of antibiotics (enrofloxacin and ciprofloxacin) can inhibit tumor cell growth and may result in synergistic tumor cell killing when combined with traditional chemotherapeutic agents. While blood and normal tissue concentrations of enrofloxacin have been reported in the dog, the achievable intratumoral concentration of these drugs has not been reported in any species. We intend to measure intratumoral concentrations of enrofloxacin and its metabolite ciprofloxacin in a variety of canine tumors to determine if the drug actually reaches the tumor in high enough concentrations to be effective.
Eligibility Requirements
All dogs must be examined by a VMTH oncology or radiation oncology service veterinarian, and require the following baseline evaluations at the owners expense before a dog can be considered for enrollment in the trial:
- Confirmed diagnosis
- Physical examination with weight recorded
- CBC, Chemistry Panel and Urinalysis All within two weeks of enrollment (referring blood work is acceptable as long as it was ran at a commercial lab)
Baseline Evaluation for Eligibility
- Histologically or cytologically confirmed disease
- Patient must be a surgery candidate.
- Informed owner consent
Benefits:
There are no direct benefits to you or your pet for enrolling your pet in this study. However, we hope that the data acquired in this study will allow us to advance the treatment of cancer in both pets and people.
Patient Disease
Patients with Splenic Hemangiosarcoma
Study Name
Adriamycin vs. Epirubicin
Purpose of the Study
Comparing Adriamycin vs. Epirubicin over the course of six doses.
Criteria
Canine patients that have Splenic Hemangiosarcoma and has ruptured with a biopsy to confirm NO liver metastasis.
Financial Incentive
There is no financial incentive. We are currently running studies to compare the use of different drugs in different combinations to provide a more effective way of treating various diseases. Your local veterinarian would call us at UCDavis to 'pull an envelope'. Each envelope is randomly pulled comparing the different drug. There is no placebo and it is 'open-label' meaning you will know exactly what drug your pet is receiving.
Patient Disease
Canine pets with Anal Sac Andenocarcinoma/Gross disease
Study Name
Carboplatin/Piroxicam vs. Mitoxantrone/Piroxicam
Purpose of the Study
Comparing the two different agents, Carboplatin/Piroxicam vs. Mitoxantrone/Piroxicam
Financial Incentive
There is no financial incentive. We are currently running studies to compare the use of different drugs in different combinations to provide a more effective way of treating various diseases. Your local veterinarian would call us at UCDavis to 'pull an envelope'. Each envelope is randomly pulled comparing the different drug. There is no placebo and it is 'open-label' meaning you will know exactly what drug your pet is receiving.
Patient Disease
Canine pets with Anal Sac Andenocarcinoma post surgery
Study Name
Carboplatin/Piroxicam vs. Mitoxantrone/Piroxicam
Purpose of the Study
Comparing the two different agents, Carboplatin/Piroxicam vs. Mitoxantrone/Piroxicam
Financial Incentive
There is no financial incentive. We are currently running studies to compare the use of different drugs in different combinations to provide a more effective way of treating various diseases. Your local veterinarian would call us at UCDavis to 'pull an envelope'. Each envelope is randomly pulled comparing the different drug. There are no placebos and it is 'open-labeled' meaning you will know exactly what drug your pet is receiving.
Patient Disease
Canine pets with TCC (Transitional Cell Carcinoma) of the bladder
Study Name
Carboplatin/Piroxicam vs. Mitoxantrone/Piroxicam
Purpose of the Study
Comparing the two different agents, Carboplatin/Piroxicam vs. Mitoxantrone/Piroxicam
Financial Incentive
There is no financial incentive. We are currently running studies to compare the use of different drugs in different combinations to provide a more effective way of treating various diseases. Your local veterinarian would call us at UCDavis to 'pull an envelope'. Each envelope is randomly pulled comparing the different drug. There is no placebo and it is 'open-label' meaning you will know exactly what drug your pet is receiving.
Patient Disease
Canine pets with Osteosarcoma
Study Name
Carboplatin vs. Adriamycin
Purpose of the Study
Comparing the two different agents, Carboplatin and Adriamycin
Financial Incentive
There is no financial incentive. We are currently running studies to compare the use of different drugs in different combinations to provide a more effective way of treating various diseases. Your local veterinarian would call us at UCDavis to 'pull an envelope'. Each envelope is randomly pulled comparing the different drug. There is no placebo and it is 'open-label' meaning you will know exactly what drug your pet is receiving.
